©2024 Stanford Medicine
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
Not Recruiting
Trial ID: NCT02175745
Purpose
To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly
diagnosed or recurrent gliomas.
Official Title
18F-FDOPA PET/CT or PET/MRI in Patients With Gliomas
Stanford Investigator(s)
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Lawrence Recht, MD
Professor of Neurology (Adult Neurology) and, by courtesy, of Neurosurgery
Eligibility
Inclusion Criteria:
- Greater than 15 year-old at the time of radiotracer administration
- Provides written informed consent
- Suspected new diagnosis or suspected recurrence of glioma
- Able to remain still for duration of each imaging procedure (about 20 minutes)
Exclusion Criteria:
- Less than 15 year-old at the time of radiotracer administra
- Unable to provide informed consent
- Inability to lie still for the entire imaging time
- Inability to complete the needed investigational and standard-of-care imaging
examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
- Any additional medical condition, serious intercurrent illness, or other extenuating
circumstance that, in the opinion of the Investigator, may significantly interfere
with study compliance
Intervention(s):
procedure: magnetic resonance imaging
drug: 18F-fluoro-dihydroxyphenylalanine
procedure: Positron emission tomography (PET)
procedure: Computed tomography (CT)
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Andrei Iagaru
650-736-2859